# A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

> **NCT02112045** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 90 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Granix
- **DRUG:** High dose melphalan (HDR)
- **PROCEDURE:** Autologous Stem Cell Transplant (ASCT)

## Key facts

- **NCT ID:** NCT02112045
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-20
- **Primary completion:** 2017-12-13
- **Final completion:** 2019-09-10
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Terminated due to results of interim analysis
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02112045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02112045, "A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02112045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*